Table 1 Characteristics and follow-up of 150 patients with PPBL
From: Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification
Age (years), Mean (min–max) | 40 (18.9–66.2) | ||
Sex (M/F) | 26 (17 %)/124 (83 %) | ||
Tobacco consumption | 130/145 (90 %) | ||
Clinical presentation | |||
Lymph node(s) | 10/108 (9 %) | ||
Splenomegaly | 19/106 (18 %) | ||
Hepatomegaly | 2/108 (2 %) | ||
Hemogram, Mean (min–max) | |||
White blood cells (109/L) | 12.8 (7–44.8) | ||
Hemoglobin (g/dL) | 13.8 (10.1–16.9) | ||
Platelets (109/L) | 228 (83–380) | ||
Lymphocytosis (109/L) | 6.5 (2.2–41) | ||
Binucleated Lymphocytes (% of lymphocytes) | 3.9 (1–40) | ||
IgM (g/L), Mean (min–max) | 7.8 (2.17–20) | ||
HLA DR7 positive | 40/52 (77 %) | ||
Multiparameter Flow Cytometry—Mean (min–max) | |||
CD19 (%) | 50.4 (7–83) | ||
Cytogenetics | Diagnosis | Follow-up | |
+i(3)(q10) positive by karyotype | 50/140 (36 %) | 20/32 (63 %) | |
+i(3)(q10) positive by FISH | 80/128 (63 %) | 24/26 (92 %) | |
PCC positive | 35/140 (25 %) | 8/32 (25 %) | |
Chromosomal instability | 76/140 (54 %) | 31/32 (97 %) | |
Subsequent Malignancies | 18/150 (12 %) | ||
MGUS | 6/150 (4 %) | ||
Non-Hodgkin’s Lymphomas | 6/150 (4 %) | ||
Solid tumors | 6/150 (4 %) |